Clinical Trials Browser

Available × INDUSTRY × Thoracic × Clear all

Carcinoma, Non-Small-Cell Lung

NCT07310277 2026-01-29

Expanded Access to ABBV-706

Available

Thoracic

Small Cell Lung Carcinoma

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Available

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05100134 2025-12-09

Managed Access Programs for LDK378, Ceritinib

Available

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT06751524 2024-12-30

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Available

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04146571 2022-10-20

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Available

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Clinical Trials

Expanded Access to Telisotuzumab Vedotin

Expanded Access to ABBV-706

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Managed Access Programs for LDK378, Ceritinib

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Expanded Access to Ensartinib for Participants With ALK+ NSCLC